Agenus | AGEN - Operating Profit


Agenus reported $14.4M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Agenus USD 14.4M 19.26M Dec/2025
Amgen USD 3.83B 130M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Celldex Therapeutics USD -87.15M 13.54M Dec/2025
CSL USD 2.64B 1.97B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Incyte USD 324.17M 59.7M Mar/2026
Intrexon USD -60.84M 26.62M Jun/2024
J&J USD 6.62B 1.03B Mar/2026
Jiangsu Hengrui CNY 2.56B 302M Mar/2026
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
MacroGenics USD -12.1M 30.74M Dec/2025
Merck EUR 474M 738M Dec/2025
Merck USD -1.88B 8.12B Mar/2026
Northwest Biotherapeutics USD -14.32M 481K Sep/2025
Novartis USD 4.24B 171M Mar/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Veracyte USD 24.63M 1.52M Dec/2025